Full-Time

Senior Scientist / Associate Director

Oligonucleotide Therapeutics

Confirmed live in the last 24 hours

Insitro

Insitro

201-500 employees

Machine learning for drug discovery efficiency

AI & Machine Learning
Biotechnology

Compensation Overview

$150k - $200kAnnually

+ Annual Performance Bonus + Equity Incentive Plan

Mid, Senior

San Bruno, CA, USA

Hybrid role based in South San Francisco headquarters with occasional travel to site.

Category
Computational Biology
Genomics
Biology & Biotech
Requirements
  • PhD in biology, biochemistry or a relevant scientific subject area, with 2-4 years of relevant experience in the field of nucleic acid therapeutics is necessary for a Sr. Scientist role. For AD, a minimum of 4-6 years of post PhD with hands on experience of the key technical requirements is necessary
  • Deep understanding of mRNA biology/regulation, RNA structure, RNA folding, and RNA chemical modifications is required
  • Knowledge of siRNA/ASO/mRNA design and MOA is necessary
  • Knowledge and experience with assays such as Taqman, western, Ago2 loading assay, RNAscope, RNAseq, Ribosome profiling, oligo stability assays will be highly valuable
  • Understanding of oligonucleotide delivery technologies will be highly valuable
  • Understanding of oligonucleotide PK/PD and IVIVC will be good to have
  • Ability to multi-task and work across teams and disease areas will be needed
Responsibilities
  • Design siRNA/ASO/mRNA for drug discovery and target validation
  • Work closely with the therapeutic teams to design experiments (in-vitro/in-vivo) required for oligonucleotide drug discovery
  • Analyze data from oligonucleotide drug discovery programs (in-vitro and in-vivo efficacy, in-vivo pk/pd, off-target profile, and metID data)
  • Apply chemical modifications to enable oligonucleotide lead optimization SAR
  • Work with AI/ML scientists to develop oligonucleotide in-silico drug design tool
  • Understand target biology and come up with novel oligonucleotide based approaches to develop therapeutics
  • Analyze data, prepare graphs/tables, and present data to a wide range of audiences
  • Keep updated with the latest developments in the field of oligotherapy and nucleic acid drug discovery

Insitro specializes in drug discovery and development by using machine learning and biological tools to predict successful paths in the pharmaceutical research process. Their predictive models help avoid costly failures by identifying promising drug candidates early on. The company collaborates with scientists and engineers to generate data that enhances the efficiency of drug development. Insitro aims to provide pharmaceutical companies and research institutions with more effective methods for discovering new medicines.

Company Stage

Series C

Total Funding

$625.5M

Headquarters

San Francisco, California

Founded

2018

Growth & Insights
Headcount

6 month growth

12%

1 year growth

22%

2 year growth

51%
Simplify Jobs

Simplify's Take

What believers are saying

  • With over $600 million in venture capital funding, Insitro is well-positioned for sustained growth and innovation in the pharmaceutical R&D sector.
  • The appointment of high-caliber professionals like Emily Fox and Philip Tagari strengthens Insitro's capabilities in AI-driven drug discovery and development.
  • Insitro's partnerships and board appointments, such as Amy Abernethy, indicate strong industry recognition and potential for impactful collaborations.

What critics are saying

  • The competitive landscape in AI-driven drug discovery is intense, with well-funded competitors like Xaira Therapeutics posing significant challenges.
  • Ethical and social justice issues related to AI in drug development, such as data privacy and diversity in clinical trials, could pose regulatory and reputational risks.

What makes Insitro unique

  • Insitro integrates machine learning with modern biological tools to create predictive models, setting it apart from traditional pharmaceutical R&D approaches.
  • The company's focus on data-driven insights and predictive modeling aims to reduce the high failure rates in drug discovery, a significant pain point in the industry.
  • Insitro's leadership team, including experts like Emily Fox and Philip Tagari, brings unparalleled expertise in AI, machine learning, and drug development, enhancing its competitive edge.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Excellent medical, dental, and vision coverage

Excellent mental health and well-being support

Open vacation policy

Access to free onsite baristas & cafe with daily lunch and breakfast

Access to free onsite fitness center

Commuter benefits

Paid parental leave

Competitive pay and 401(k) matching

Flexible work schedule (on site and remote)